6-K ·Filed Jun 25, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor clinical data readout at ICNMD on July 8. Positive efficacy or safety signals could drive share movement, but the filing is a routine conference announcement with no pre-released results.
Final — all horizons settled through T+60d
MSLE ▲ +38.90% at T+60d
NEUTRAL call +38.90% · α vs SPY +35.04% · entry $6.71 → $9.32
T+1d
+5.51%
call +5.51% · α +6.24%
$7.08
settled 4mo ago
T+5d
+12.97%
call +12.97% · α +11.41%
$7.58
settled 4mo ago
T+20d
+43.37%
call +43.37% · α +42.84%
$9.62
settled 3mo ago
T+60d
+38.90%
call +38.90% · α +35.04%
$9.32
settled 5w ago
Price Chart
Loading chart...
Executive Summary
Satellos announced a poster and showcase presentation at ICNMD 2026 covering six-month follow-up data from its Phase 1b SAT-3247-CL-101 trial and ongoing Phase 2 TRAILHEAD study. No financial or material operational updates were provided.
Key Facts
- New SAT-3247 clinical data to be presented at ICNMD 2026 (July 8-11, Florence, Italy).
- Poster on six-month follow-up from Phase 1b completers enrolled in Phase 2 TRAILHEAD.
- Showcase theatre presentation on SAT-3247 mechanism and clinical progress.
- SAT-3247 is an oral AAK1 inhibitor targeting muscle regeneration in Duchenne muscular dystrophy (dystrophin-independent).
Financial Impact
Not specified
Risk Factors
- Clinical trial failure risk; no efficacy data disclosed yet.
- Biotech sector volatility; binary event risk around data presentation.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004290 |
| Document: f6k_062426.htm | 0001171843-26-004290 |
| Document: 0001171843-26-004290-index-headers.html | 0001171843-26-004290 |
| Document: 0001171843-26-004290-index.html | 0001171843-26-004290 |
| Document: 0001171843-26-004290.txt | 0001171843-26-004290 |
22 reports for MSLE
71% Hit rate @ T+20 Went positive at some point 5 of 8 best @ T+20▲ +23.95%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
Showing 10 of 22
US Market Status
Market Closed — Opens Wed (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers